Late-stage biopharmaceutical company, Cytokinetics, Incorporated, is dedicated to discovering, developing, and commercializing muscle activators and inhibitors to address debilitating diseases. With a focus on small molecule drug candidates engineered to impact muscle function and contractility, the company is at the forefront of muscle biology research. Among its leading drug candidates is omecamtiv mecarbil, a novel cardiac myosin activator currently in Phase III clinical trial in patients with heart failure, as well as reldesemtiv, a skeletal muscle troponin activator in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. Additionally, Cytokinetics, Incorporated is pursuing the development of CK-136, a novel cardiac troponin activator currently in Phase I clinical trial, and aficamten, a novel cardiac myosin inhibitor in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company is headquartered in South San Francisco, California and boasts a strategic alliance with Astellas Pharma Inc. since its incorporation in 1997.